文献速递系统性红斑狼疮

泰它西普治疗儿童起病系统性红斑狼疮的前瞻性多中心队列研究

Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab.
PubMed 文献 · Arthritis Rheumatol · 2025-12-28

这项前瞻性多中心队列研究纳入60例5至18岁儿童起病系统性红斑狼疮患者,评估泰它西普联合标准治疗对比贝利尤单抗联合标准治疗(历史对照组67例)的疗效。经IPTW调整后,两组在LLDAS、DORIS达标、激素减量及免疫学正常化方面均无显著差异(均P>0.05)。泰它西普组12个月LLDAS达标率65.7%、DORIS达标率37.1%。

要点

  • 泰它西普组12个月LLDAS达标率65.7%,DORIS达标率37.1%。
  • 泰它西普组12个月泼尼松剂量≤7.5 mg/天者占74.3%,基线为13.3%(P<0.0001)。
  • IPTW调整后泰它西普与贝利尤单抗组所有终点均无显著差异(均P>0.05)。

核心结论

  • 泰它西普联合标准治疗在儿童起病系统性红斑狼疮中表现出疾病活动度、激素减量及免疫学指标的显著改善,疗效与贝利尤单抗相当。

研究设计与样本

  • 前瞻性队列研究,纳入中国七家三级医院年龄5至18岁的儿童起病系统性红斑狼疮患者,泰它西普组60例,贝利尤单抗历史对照组67例,采用倾向性评分逆概率治疗加权(IPTW)调整基线失衡。

主要发现

  • 泰它西普组60例患者中位随访12个月(四分位距6-12个月),LLDAS达标率从6个月19.6%升至12个月65.7%,DORIS达标率从6个月7.8%升至12个月37.1%。
  • 泰它西普组复发率3个月为1.7%、6个月为11.8%、12个月为14.3%。
  • 泰它西普组12个月泼尼松剂量≤7.5 mg/天者占74.3%,基线为13.3%(P<0.0001)。
  • IPTW调整后,泰它西普组与贝利尤单抗组在LLDAS和DORIS达标、激素减量及免疫学正常化所有终点上均无显著差异(均P>0.05)。

关键数值与推荐

  • 主要终点为治疗3、6、12个月时LLDAS和DORIS达标比例,辅以复发率和激素减量指标。

临床怎么用

  • 泰它西普联合标准治疗可作为儿童起病系统性红斑狼疮的治疗选择,疗效与贝利尤单抗联合标准治疗相当。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood-onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC. METHODS: We performed a prospective cohort study across seven tertiary hospitals in China, enrolling patients aged 5 to 18 years with cSLE. Primary endpoints included the proportions of patients attaining Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) at 3, 6, and 12 months after treatment, complemented by relapse rates and steroid tapering metrics. Propensity score-based inverse probability of treatment weighting (IPTW) was employed to address baseline imbalances between the telitacicept group (n = 60) and the historical control group treated with belimumab (n = 67). RESULTS: Among 60 enrolled patients (median follow-up 12 [interquartile range 6-12] months), LLDAS and DORIS achievement rates progressively increased from 19.6% and 7.8% at 6 months to 65.7% and 37.1% at 12 months. Flare rates remained low (3 months: 1.7%; 6 months: 11.8%; 12 months: 14.3%). Notably, 74.3% of patients achieved prednisone doses ≤7.5 mg/day by 12 months (vs baseline 13.3%, P < 0.0001). IPTW-adjusted analyses demonstrated comparable efficacy between the telitacicept and belimumab groups across all endpoints in terms of LLDAS and DORIS attainment, steroid reduction, and immunologic normalization (all P > 0.05). CONCLUSION: Telitacicept combined with SoC exhibited significant improvements in disease activity, steroid reduction, and immunologic markers, with therapeutic outcomes comparable to belimumab in cSLE management.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Luo C, Su S, Liu J, et al. Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab. Arthritis Rheumatol. 2025. PMID: 41147706. doi:10.1002/art.43417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。